Taken at face value, the latest figures on Attention Deficit Hyperactivity Disorder (ADHD) suggest a growing epidemic in the United States. According to the Centers for Disease Control, 15 percent of high school children are diagnosed with ADHD. The number of those on stimulant medication is at 3.5 million, up from 600,000 two decades ago. ADHD is now the second most common long-term diagnosis in children, narrowly trailing asthma. But a new report in the New York Times questions whether these staggering figures reflect a medical reality, or an over-medicated craze that has earned billions in profits for the pharmaceutical companies involved.
Sales for ADHD drugs like Adderall and Concerta topped $9 billion in the United States last year, a more than 500 percent jump from a decade before. The radical spike in diagnoses has coincided with a 20-year marketing effort to promote stimulant prescriptions for children struggling in school, as well as for adults seeking to take control of their lives. The marketing effort has relied on studies and testimonials from a select group of doctors who have received massive speaking fees and funding grants from major pharmaceutical companies. We are joined by four guests: Alan Schwarz, an award-winning reporter who wrote the New York Times piece, “The Selling of Attention Deficit Disorder”; Jamison Monroe, a former teenage Adderall addict who now runs Newport Academy, a treatment center for teens suffering from substance abuse and mental health issues; Dr. Gabor Maté, a physician and bestselling author of four books, including “Scattered: How Attention Deficit Disorder Originates and What You Can Do About It”; and John Edwards, the father of a college student who committed suicide after he was prescribed Adderall and antidepressant medications at the Harvard University Health Services clinic.
(Via Democracy Now)